Skip to content

VERTEX PHARMACEUTICALS INC / MA

VRTX

CIK 0000875320

← back to feed
Revenue (TTM)
$11.8B
+8.9% YoY Q1 Apr 2026
Net Income (TTM)
$3.79B
+838.1% YoY Q1 Apr 2026
EPS Diluted (TTM)
$14.70
+836.5% YoY Q1 Apr 2026
Gross Margin
86.6%
Q1 Apr 2026
Operating Margin
34.8%
Q1 Apr 2026
Net Margin
32.2%
Q1 Apr 2026
Free Cash Flow (TTM)
$4.17B
Q1 Apr 2026
Cash
$5.49B
Q1 Apr 2026
Total Debt
$105M
Q1 Apr 2026
Shares Outstanding
253.81M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings